Fig. 1.

Computed tomographic (CT) scan (top) and somatostatin receptor scintigraphy (SRS) (bottom) results in a patient with previously resected pancreatic neuroendocrine tumor (pNET). This patient previously (2 years prior) had a pNET resected and during follow up the CT scan was negative, as was the magnetic resonance imaging (MRI) scan and abdominal ultrasound (not shown); however, SRS performed with ¹¹¹In-penetreotide (Octreoscan) demonstrated metastases both in the liver and in lymph nodes. These results illustrate the greater sensitivity of SRS over conventional imaging studies (CT, ultrasound, MRI) for detecting metastases in patients with malignant pNETs [3, 14, 25, 26, 71, 72]